- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07588217
Ondansetron for the Prevention of Patient Self-Inflicted Lung Injury in Patients With ARDS - Pilot RCT (OSIRIS-1)
A Pilot, Randomized, Controlled Clinical Trial Evaluating Ondansetron for the Prevention of Patient Self-Inflicted Lung Injury Through Inhibition of Respiratory Drive in Patients With Acute Respiratory Distress Syndrome (OSIRIS-1)
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
BACKGROUND: Acute Respiratory Distress Syndrome (ARDS) is a life-threatening inflammatory lung condition with high mortality and long-term morbidity. Lung-protective ventilation - targeting low tidal volumes and driving pressures - is one of the few proven interventions but often requires deep sedation and neuromuscular blockade (NMB), which are associated with delirium, ICU-acquired weakness, and prolonged ICU stays. Maintaining spontaneous breathing can offer physiological advantages but is frequently limited by excessive respiratory drive, which increases the risk of patient self-inflicted lung injury (P-SILI). Lung inflammation leading to stimulation and sensitization of pulmonary vagal afferent Cfibers could contribute to excessive respiratory effort. Stimulation of pulmonary C-fibers by serotonin increases respiratory rate in animal models through 5-HT receptors. Our previous data suggest that 3 ondansetron, a 5-HT receptor antagonist, attenuates respiratory drive and effort. We hypothesize that 3 this effect may reduce the need for sedation and paralysis, minimize P-SILI, and ultimately improve outcomes in ARDS.
OBJECTIVES: The overarching goal of the OSIRIS research program is to evaluate whether regular intravenous ondansetron can improve patient-important outcomes (survival, ventilator-free days and long term neurocognitive function) in patients with ARDS. With the OSIRIS-1 pilot study, our objective is to assess:
Feasibility:
[RQ1] What is the adherence to the study protocol? [PRIMARY] [RQ2] What is the completeness of the data collection? [RQ3] What is the recruitment rate?
Preliminary mechanistic efficacy and safety:
[RQ4] Does it decrease respiratory effort? [RQ5] Does it reduce exposure to sedatives, opioids and neuromuscular blockers? [RQ6] Is the intervention safe?
METHODS: OSIRIS-1 is a multicenter, double-blind, parallel-group, phase 2 and feasibility pilot RCT. We will enroll 76 invasively mechanically ventilated adults with moderate-to-severe ARDS (PaO :FiO2 < 200). Participants will be randomized to receive ondansetron 8 mg IV or placebo every 8 hours until liberation from invasive mechanical ventilation. Feasibility will be assessed through protocol adherence (defined as scheduled doses administered within ±2 hours), completeness of key clinical outcomes (ventilator-free days, coma/delirium-free days, 90-day survival), and site-level recruitment metrics. For preliminary efficacy, we will estimate respiratory drive using Pmus (derived from occlusion pressure, ΔPocc), measured three times daily by respiratory therapists. We will also measure P0.1, respiratory rate, and other ventilatory parameters. For safety, we will monitor the occurrence of ventricular arrhythmias, serotonin syndrome, and other serious adverse events.
IMPACT: OSIRIS-1 will provide essential data on mechanistic efficacy, safety, and feasibility to inform the design of a future large-scale trial evaluating patient-important outcomes. By targeting respiratory drive pharmacologically, we may enable safer spontaneous breathing, reduce the harms of oversedation and paralysis, and ultimately improve outcomes in ARDS.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
- Fas 3
Kontakter och platser
Studiekontakt
- Namn: Virginie Williams, PhD
- Telefonnummer: 5833272 514-338-2222
- E-post: eresi.cnmtl@ssss.gouv.qc.ca
Studieorter
-
-
Quebec
-
Montreal, Quebec, Kanada, H4J 1C5
- Hôpital du Sacré-Cœur de Montréal
-
Kontakt:
- Virginie Williams, PhD
- Telefonnummer: 5833272 514-338-2222
- E-post: eresi.cnmtl@ssss.gouv.qc.ca
-
Huvudutredare:
- Yiorgos Alexandros Cavayas, MD MSc
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Beskrivning
Inclusion Criteria:
- Moderate-to-severe ARDS with all of the following:
- Hypoxemic respiratory failure with PaO2:FiO2 < 200 (on IMV with PEEP ≥ 5)
- Precipitated within 1 week of an acute condition
- Bilateral opacities on chest radiography and computed tomography or bilateral B lines and/or consolidations on ultrasound not fully explained by effusions, atelectasis, or nodules/masses
- Pulmonary edema not exclusively or primarily attributable to cardiogenic pulmonary edema/fluid overload
- Hypoxemia/gas exchange abnormalities not primarily attributable to atelectasis
- IMV initiated < 96 hours
- Extubation not anticipated within 24 hours
Exclusion Criteria:
- Neuromuscular disease impairing spontaneous breathing
- Pregnancy
- Liver cirrhosis (Child B or C) or other severe impairment of hepatic function
- Bradycardia (baseline pulse<50/min) on screening day
- Known long QT syndrome
- History of sustained ventricular tachycardia
- Active digestive / abdominal infection44
- QTc prolongation > 470 msec in men and > 480 msec in women on screening day
- On a medication at high risk of QT prolongation (Table 5)50
- On two or more serotonergic medications (Table 6)51
- Hypersensitivity / intolerance to 5-HT3 antagonists
- Patient deemed unlikely to survive past 24 hours or being transitioned to a fully palliative philosophy of care
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Ondansetron
The first dose of intravenous ondansetron will be administered within 24 hours of randomization, every 8 hours, for duration of invasive mechanical ventilation.
|
Participants randomized to the ondansetron arm will receive ondansetron hydrochloride dihydrate 8 mg IV every 8 hours, administered in 10 mL of 0.9% sodium chloride in prepared syringes over 15 minutes.
|
|
Placebo-jämförare: Placebo
The first dose of intravenous placebo will be administered within 24 hours of randomization, every 8 hours, for duration of invasive mechanical ventilation.
|
Participants randomized to the placebo arm will receive 10 mL of 0.9% sodium chloride in prepared syringes administered over 15 minutes every 8 hours, matching the appearance, volume, and administration modalities of ondansetron to maintain blinding.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
protocol adherence
Tidsram: duration of intervention (duration of invasive mechanical ventilation)
|
Adherence will be measured as the proportion of scheduled doses (±2h window) administered; protocol-defined withholdings (e.g., electrophysiological disturbances) will be documented but not counted as non-adherence.
|
duration of intervention (duration of invasive mechanical ventilation)
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Outcome data completeness
Tidsram: 90 days
|
Data completeness for 90 day survival, 28 day ventilator-free days, and 14 day coma-and-delirium-free days.
|
90 days
|
|
Enrolment rate
Tidsram: Duration of the study
|
Patients enrolled by site by 12-month period
|
Duration of the study
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Pmus
Tidsram: duration of the intervention (duration of invasive mechanical ventilation)
|
Pmus will be estimated by the occlusion pressure maneuvre, measured 3 times per day.
|
duration of the intervention (duration of invasive mechanical ventilation)
|
|
P0.1
Tidsram: duration of the intervention (duration of invasive mechanical ventilation)
|
P0.1 will be measured 3 times per day.
|
duration of the intervention (duration of invasive mechanical ventilation)
|
|
Respiratory Rate
Tidsram: duration of the intervention (duration of invasive mechanical ventilation)
|
Respiratory Rate will be measured 3 times per day.
|
duration of the intervention (duration of invasive mechanical ventilation)
|
|
Tidal volume
Tidsram: duration of the intervention (duration of invasive mechanical ventilation)
|
Tidal volume will be measured 3 times per day.
|
duration of the intervention (duration of invasive mechanical ventilation)
|
|
PaO2:FiO2 ratio
Tidsram: duration of the intervention (duration of invasive mechanical ventilation)
|
PaO2:FiO2 ratio will be measured 3 times per day.
|
duration of the intervention (duration of invasive mechanical ventilation)
|
|
Number of days of deep sedation
Tidsram: duration of the intervention (duration of invasive mechanical ventilation)
|
A deep sedation will be defined as a day in which a Richmond Agitation and Sedation Scale (RASS) of -4 or -5 was present for the majority of the day
|
duration of the intervention (duration of invasive mechanical ventilation)
|
|
Average daily oral morphine equivalent
Tidsram: duration of the intervention (duration of invasive mechanical ventilation)
|
All opiates received during a given day will be converted in oral morphine equivalent and summed up.
|
duration of the intervention (duration of invasive mechanical ventilation)
|
|
Days with NMB administration
Tidsram: duration of the intervention (duration of invasive mechanical ventilation)
|
Defined by having received any dose or neuromuscular blocker during a given day.
|
duration of the intervention (duration of invasive mechanical ventilation)
|
|
Sustained Ventricular Arrhythmia
Tidsram: duration of the intervention (duration of invasive mechanical ventilation)
|
Defined as ventricular tachycardia or fibrillation sustained for ≥30 seconds or requiring termination due to hemodynamic compromise in <30 seconds.
|
duration of the intervention (duration of invasive mechanical ventilation)
|
|
Serotonin Syndrome
Tidsram: duration of the intervention (duration of invasive mechanical ventilation)
|
Serotonin syndrome (ie, serotonin toxicity) is a potentially life-threatening condition associated with increased serotonergic activity in the central nervous system.
It is seen with therapeutic medication use, inadvertent interactions between drugs, and intentional self-poisoning.
Serotonin syndrome may involve a spectrum of clinical findings, which often include mental status changes, autonomic hyperactivity, and neuromuscular abnormalities.
|
duration of the intervention (duration of invasive mechanical ventilation)
|
|
90-day survival
Tidsram: 90 days
|
Being alive at 90 days
|
90 days
|
|
Ventilator-Free Days
Tidsram: 28 days
|
Number of days alive and free of mechanical ventilation in the first 28 days with death before day 28 counted as 0
|
28 days
|
|
Coma-and-delirium-free days
Tidsram: 14 days
|
Number of days alive without delirium nor coma from any cause in the first 14 days
|
14 days
|
Samarbetspartners och utredare
Utredare
- Huvudutredare: Yiorgos Alexandros Cavayas, MD MSc, Centre Intégré Universitaire de Santé et Services Sociaux du Nord-de-l'Ile-de-Montréal - Hôpital du Sacré-Coeur de Montréal
- Huvudutredare: David Williamson, BPharm, PhD, Centre Intégré Universitaire de Santé et Services Sociaux du Nord-de-l'Ile-de-Montréal - Hôpital du Sacré-Coeur de Montréal
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Luftvägssjukdomar
- Lungsjukdomar
- Lungskada
- Akut lungskada
- Heterocykliska föreningar, 1-ring
- Heterocykliska föreningar
- Heterocykliska föreningar, 2-ring
- Heterocykliska föreningar, smältring
- Farmaceutiska förberedelser
- Azoler
- Imidazoler
- Förenad
- Kristalloidlösningar
- Isotonlösningar
- Lösningar
- Heterocykliska föreningar, 3-ring
- Karbasol
- Ondansetron
- Saltlösning
Andra studie-ID-nummer
- MP-32-2026-3061
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .